Late-breaking Trials from the 2016 American Heart Association's Scientific Sessions

Kyle D. Buchanan; M. Chadi Alraies; Alexandre H. Kajita; Toby Rogers; Edward Koifman; Arie Steinvil

doi:10.1016/j.carrev.2016.12.002

Late-breaking Trials from the 2016 American Heart Association's Scientific Sessions

Kyle D. Buchanan^*
, M. Chadi Alraies
, Alexandre H. Kajita
, Toby Rogers
, Edward Koifman
, Arie Steinvil

^*Corresponding author for this work

Washington Hospital Center

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

The late breaking trials released at the American Heart Association scientific sessions conference in November in New Orleans, LA covered a wide range of topics, including new devices within the field of heart failure, new registry data on transcatheter aortic valve replacement (TAVR) in intermediate risk patients, and medical management of peripheral arterial disease, coronary artery disease, and hypercholesterolemia. The following review highlights the late breaking trials presented at the conference that will have significant impact on clinical practice.

Original language	English
Pages (from-to)	70-74
Number of pages	5
Journal	Cardiovascular Revascularization Medicine
Volume	18
Issue number	1
DOIs	https://doi.org/10.1016/j.carrev.2016.12.002
State	Published - 1 Jan 2017
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Atrial fibrillation
Coronary artery disease
Heart failure
Transcatheter aortic valve replacement

Access to Document

10.1016/j.carrev.2016.12.002

Cite this

@article{5f561e2505ac40619ff2781f919fd4c8,

title = "Late-breaking Trials from the 2016 American Heart Association's Scientific Sessions",

abstract = "The late breaking trials released at the American Heart Association scientific sessions conference in November in New Orleans, LA covered a wide range of topics, including new devices within the field of heart failure, new registry data on transcatheter aortic valve replacement (TAVR) in intermediate risk patients, and medical management of peripheral arterial disease, coronary artery disease, and hypercholesterolemia. The following review highlights the late breaking trials presented at the conference that will have significant impact on clinical practice.",

keywords = "Atrial fibrillation, Coronary artery disease, Heart failure, Transcatheter aortic valve replacement",

author = "Buchanan, \{Kyle D.\} and Alraies, \{M. Chadi\} and Kajita, \{Alexandre H.\} and Toby Rogers and Edward Koifman and Arie Steinvil",

note = "Publisher Copyright: {\textcopyright} 2016",

year = "2017",

month = jan,

day = "1",

doi = "10.1016/j.carrev.2016.12.002",

language = "אנגלית",

volume = "18",

pages = "70--74",

journal = "Cardiovascular Revascularization Medicine",

issn = "1553-8389",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Late-breaking Trials from the 2016 American Heart Association's Scientific Sessions

AU - Buchanan, Kyle D.

AU - Alraies, M. Chadi

AU - Kajita, Alexandre H.

AU - Rogers, Toby

AU - Koifman, Edward

AU - Steinvil, Arie

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The late breaking trials released at the American Heart Association scientific sessions conference in November in New Orleans, LA covered a wide range of topics, including new devices within the field of heart failure, new registry data on transcatheter aortic valve replacement (TAVR) in intermediate risk patients, and medical management of peripheral arterial disease, coronary artery disease, and hypercholesterolemia. The following review highlights the late breaking trials presented at the conference that will have significant impact on clinical practice.

AB - The late breaking trials released at the American Heart Association scientific sessions conference in November in New Orleans, LA covered a wide range of topics, including new devices within the field of heart failure, new registry data on transcatheter aortic valve replacement (TAVR) in intermediate risk patients, and medical management of peripheral arterial disease, coronary artery disease, and hypercholesterolemia. The following review highlights the late breaking trials presented at the conference that will have significant impact on clinical practice.

KW - Atrial fibrillation

KW - Coronary artery disease

KW - Heart failure

KW - Transcatheter aortic valve replacement

UR - https://www.scopus.com/pages/publications/85010369437

U2 - 10.1016/j.carrev.2016.12.002

DO - 10.1016/j.carrev.2016.12.002

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 28131332

AN - SCOPUS:85010369437

SN - 1553-8389

VL - 18

SP - 70

EP - 74

JO - Cardiovascular Revascularization Medicine

JF - Cardiovascular Revascularization Medicine

IS - 1

ER -

Late-breaking Trials from the 2016 American Heart Association's Scientific Sessions

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this